Neogen Sells Animal Genomics Business to Zoetis for $160 Million
summarizeSummary
Neogen Corp. has announced the sale of its animal genomics business to Zoetis Inc. for $160 million. This divestiture represents a material transaction for Neogen, equating to approximately 6.5% of its current market capitalization. The move could be a strategic effort to streamline operations and strengthen its financial position, especially following its recent 10-Q which disclosed material weaknesses in internal controls and ongoing shareholder lawsuits related to its 3M acquisition. For Zoetis, this acquisition is aimed at accelerating precision animal health innovation. Investors will be watching how Neogen utilizes the proceeds from this sale and the subsequent impact on its financial performance and strategic focus.
At the time of this announcement, NEOG was trading at $11.47 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.4B. The 52-week trading range was $3.87 to $11.43. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.